Asuragen, Inc. products

Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX^® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.

The QuantideX^® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX^® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.